ClinicalTrials.gg
CompletedNCT06128382Updated Sep 10, 2026

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

A Phase 1 interventional study of OVX033 and Saline solution in Coronavirus, sponsored by Osivax. Completed at 1 site in France. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Osivax · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 89 studies in Coronavirus Infections with a site in France — 4 open to participants now, 6 under way, 2 of them phase 3. Coronavirus Infections · France.

Enrollment
35th of 45
48 · median 228
Started
2024
the only one that year
Phase 1
3 of 89
none open now
Registered
87th of 89
by date

Among the 89 studies in Coronavirus Infections with a site in France, this one is the 35th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 1, and was the 87th registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 51 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

4 of the 89 studies in Coronavirus Infections with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Coronavirus Infections studies recruiting now, 23 (59%) set no upper age limit and 9 (23%) stop at 75 or younger; 12 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Coronavirus Infections with a site in France, or all of them as a file.
02

Study summary

This first-in-human clinical trial is designed to evaluate the safety and immunogenicity of one administration of OVX033 coronavirus vaccine at different dose levels (100µg, 250µg and 500µg)

Read the detailed description

This trial is a first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study in 48 adult subjects to evaluate the safety and immunogenicity of OVX033 sarbecovirus vaccine at different dose levels (100µg, 250µg and 500µg).

One single dose of OVX033 vaccine or of Placebo will be administered intramuscularly in healthy subjects aged 18-49 years.

03

Conditions studied

  • Coronavirus
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written .
  2. Healthy male or female subjects, as determined by medical history and medical examination.
  3. Aged 18 to 49 years.
  4. Subjects who have been vaccinated (2 to 4 doses) with a licensed SARS-CoV-2 (COVID-19) vaccine. The last dose should be >6 months before administration of the vaccine.
  5. Reliable and willing to make themselves available for the duration of the study, willing and able to follow study procedures.
  6. Willing to refrain from strenuous physical exercise during the week preceding any blood sampling, including between screening and vaccination visit (Visit 2).

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a (BMI) \<18 kg/m² or >30 kg/m² at screening.
  2. Subjects weighing less than 50 kg.
  3. Subjects with abnormal safety laboratory (hematology, biochemistry, coagulation and urinalysis) parameter at screening.
  4. Subjects having previously received a non-licensed SARSCoV-2 vaccine or only one single dose of a licensed SARSCoV-2 vaccine.
  5. Subjects having presented medically significant adverse event after having received a SARS-CoV-2 licensed vaccine.
  6. Subjects currently treated with medications intended to prevent SARS-CoV-2 infection or disease (COVID-19) complications.
  7. SARS-CoV-2 infection within the past 3 months prior to enrolment, RT-PCR-confirmed SARS-CoV-2 infection at screening or ongoing symptom of COVID-19.
  8. Subjects having received another vaccination within 3 months prior to the day of study vaccination for , or within 1 month prior to the day of study vaccination for inactivated vaccines.
  9. Planning to receive other vaccines during the first 28 days following the study vaccine administration.
  10. Female subjects: pregnant, breast-feeding or of without appropriate methods in place for at least 2 months before enrolment, or with positive pregnancy test at screening or on the day of vaccination. Appropriate contraceptive methods are to be maintained until the end of the trial.
  11. Subjects receiving treatment that can affect immune response such as systemic or high dose inhaled (>800μg/day beclomethasone or equivalent; occasional inhaled corticosteroids for asthma therapy are allowed), radiation treatment, cytotoxic drugs, or current or recent (within 3 months before study entry) chronic or prolonged (>10 days) use of systemic non-steroidal anti-inflammatory drugs, interferon, immunomodulators, allergy shots, as judged by the Investigator.
  12. Any known or suspected immunodeficient conditions.
  13. Past or current history of significant diseases, as judged by the Investigator.
  14. Known or suspected infection with (HIV), virus (HCV), or virus (HBV) at screening.
  15. Current history of medical illness such as diabetes, hypertension, heart, renal or hepatic diseases, as judged by the Investigator.
  16. Hereditary or acquired hemorrhagic tendency or coagulation dysfunction (e.g., cytokine defects, coagulation disorders or disorder), or history of serious bleeding, or history of massive bleeding after intramuscular injection, intravenous puncture or ecchymosis.
  17. History of receiving blood, blood components or immunoglobulins within 3 months prior to the day of vaccination, or planned to receive such product during the whole study period.
  18. Presence of an acute febrile illness on the day of planned vaccination or within 72 hours prior of it (oral temperature>38.0°C; temporary exclusion criterion).
  19. Past or current history of any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.
  20. Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study.
  21. Past (stopped less than 6 months before enrolment) or current smoking habit above 10 cigarettes per day.
  22. Past (stopped less than 6 months before enrolment) or current history of alcohol consumption (more than 2 glasses per day, more than 10 glasses per week, or absence of any days within a week without consumption. A standard glass contains 10 g of alcohol corresponding to 10 cl of wine, 25 cl of beer at 5% or 3 cl of alcohol at 40% [Société Française d'Alcoologie, 2023]).
  23. Past (stopped less than 6 months before enrolment) or current history of use of recreational drugs.
  24. Prophylactic or therapeutic use of any anti(retro)virals by systemic route during the study. Topical application is allowed.
  25. History of severe allergic reactions and/or anaphylaxis, or serious adverse reactions to vaccines or allergy to kanamycin.
  26. Any to intramuscular administration, as judged by the Investigator.
  27. Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study, or pose additional risk to the subjects due to participation in the study, either directly or through any treatments administered for that illness.
  28. Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse (or assimilated), parent, child or sibling, whether biological or legally adopted.
  29. Subjects receiving ≥10 mg/day of prednisone or equivalent for more than 3 months before study entry.
  30. Health professionals and/or students for whom vaccination against SARS-CoV-2 is strongly recommended.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    OVX033 - 100µg dose level

    Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 100µg (0.2mL) dose on Day 1.

    Biological: OVX033

  • Experimental
    OVX033 - 250µg dose level

    Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 250µg (0.5mL) dose on Day 1.

    Biological: OVX033

  • Experimental
    OVX033 - 500µg dose level

    Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 500µg (1.0mL) dose on Day 1.

    Biological: OVX033

  • Placebo comparator
    Saline solution - 0.2mL

    Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.2mL dose on Day 1.

    Biological: Saline solution

  • Placebo comparator
    Saline solution - 0.5mL

    Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.5mL dose on Day 1.

    Biological: Saline solution

  • Placebo comparator
    Saline solution - 1.0mL

    Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 1.0mL dose on Day 1.

    Biological: Saline solution

Interventions

  • BiologicalOVX033

    One single administration intramuscularly on Day 1

  • BiologicalSaline solution

    One single administration intramuscularly on Day 1

06

What researchers measure

Primary outcomes

  1. Number and percentage of subjects reporting solicited local (Injection site redness, Injection site swelling, Injection site pain) and systemic (Fatigue, Headache, Arthralgia, Malaise, Myalgia, Fever) signs and symptoms

    Time frame: during 7 days after vaccine administration

  2. Number and percentage of subjects reporting unsolicited adverse events

    Time frame: during 29 days after vaccine administration

  3. Occurrence of adverse event of special interest

    Time frame: during the whole study duration, 180 days

  4. Occurrence of serious adverse event

    Time frame: during the whole study duration, 180 days

  5. Number and percentage of subjects with medically-attended adverse events (classified by type and reason)

    Time frame: during the whole study duration, 180 days

  6. Number and percentage of subjects with deviations from normal values (judged clinically relevant or not by the Investigator) of safety laboratory tests

    Time frame: during 29 days after vaccine administration

Secondary outcomes

  1. Cell-mediated immune response in terms of change of N-specific T-cell number in PBMCs, measured by IFNγ ELISPOT (after in vitro stimulation)

    Time frame: at Days 8, 29, 90 and 180 versus pre-injection baseline (Day 1)

  2. N-specific CD4+ and CD8+T-cell percentages measured by flow cytometry (on PBMCs), identified as expressing markers (after in vitro stimulation), such as IL-2, TNFα and/or IFNγ

    Time frame: at Day 1 (pre-injection baseline) and Days 8 and 29

  3. Geometric mean titers (GMTs) of anti-N IgG (ELISA, serum)

    Time frame: at Day 1 (pre-injection baseline), and Days 8, 29, 90 and 180

  4. Number and percentage of subjects with an increase (four-fold) in anti-N IgG titer

    Time frame: on Days 8, 29, 90 and 180, with respect to preinjection baseline (Day 1)

  5. Anti-OVX313 IgG (ELISA, serum) titers

    Time frame: at Days 29, 90 and 180 versus pre-injection baseline (Day 1)

  6. anti-hC4BP oligomerization domain IgG (ELISA, serum) titers [If positive result for anti-OVX313]

    Time frame: at Days 29, 90 and 180 versus pre-injection baseline (Day 1)

  7. Number and percentage of subjects with a RT-PCR-confirmed SARS-CoV-2 and/or influenza A or B infection

    Time frame: during the whole study duration, 180 days

07

Study locations

1 site
  • CIC Cochin Pasteur CIC 1417 Hôpital Cochin
    Paris, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jul 2024, 6 months.

Of 35 industry-sponsored phase 1 interventional studies under Coronavirus Infections, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 61 studies reached it within 10 months; a quarter within 3 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Jan 8, 2024
Primary completionActual
Jul 8, 2024
CompletionActual
Nov 29, 2024
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06128382
Lead sponsor
Osivax
Collaborators
CIC 1417 Cochin Pasteur Hôpital Cochin Paris France
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Jan 8, 2024
Primary completion
Jul 8, 2024
Completion
Nov 29, 2024
Last update
Sep 10, 2026

Study contacts

Odile Launay, MD
principal investigator · CIC Cochin Pasteur CIC 1417 Hôpital Cochin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion